Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNMD 
CONMED Corporation (CNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: CNMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $66.6
1 Year Target Price $66.6
| 0 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.26% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.68B USD | Price to earnings Ratio 14.26 | 1Y Target Price 66.6 |
Price to earnings Ratio 14.26 | 1Y Target Price 66.6 | ||
Volume (30-day avg) 6 | Beta 1.24 | 52 Weeks Range 45.83 - 77.23 | Updated Date 07/4/2025 |
52 Weeks Range 45.83 - 77.23 | Updated Date 07/4/2025 | ||
Dividends yield (FY) 1.54% | Basic EPS (TTM) 3.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.02% | Operating Margin (TTM) 7.27% |
Management Effectiveness
Return on Assets (TTM) 4.14% | Return on Equity (TTM) 12.96% |
Valuation
Trailing PE 14.26 | Forward PE 27.03 | Enterprise Value 2537634865 | Price to Sales(TTM) 1.28 |
Enterprise Value 2537634865 | Price to Sales(TTM) 1.28 | ||
Enterprise Value to Revenue 1.93 | Enterprise Value to EBITDA 10.02 | Shares Outstanding 30939900 | Shares Floating 30662953 |
Shares Outstanding 30939900 | Shares Floating 30662953 | ||
Percent Insiders 0.58 | Percent Institutions 117.51 |
Upturn AI SWOT
CONMED Corporation
Company Overview
History and Background
CONMED Corporation was founded in 1970. Initially focused on electrosurgical products, it has grown through acquisitions and organic growth to become a diversified medical technology company.
Core Business Areas
- Orthopedic Surgery: Provides a comprehensive suite of products for arthroscopic sports medicine and orthopedic reconstructive procedures.
- General Surgery: Offers a wide range of products for minimally invasive and open surgical procedures, including advanced energy, smoke evacuation, and surgical visualization products.
Leadership and Structure
CONMED is led by its CEO and operates under a board of directors. The company has a functional organizational structure, with departments such as sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- Advanced Surgical: Includes products for advanced energy, such as electrosurgical generators and handpieces. Competitors include Medtronic, Ethicon (Johnson & Johnson).
- Orthopedics: Encompasses arthroscopic solutions, including surgical tools, implants, and fluid management systems. Competitors include Stryker, Arthrex, and Smith & Nephew.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth due to an aging population, increasing demand for minimally invasive procedures, and technological advancements. It is heavily regulated and subject to intense competition.
Positioning
CONMED holds a strong position in the orthopedic and general surgery markets. Its competitive advantages include a diversified product portfolio and strong brand recognition.
Total Addressable Market (TAM)
The global medical devices market is estimated to be worth hundreds of billions of dollars. CONMED is positioned to capture a portion of this TAM through its focused product offerings and geographic expansion.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Established brand reputation
- Strong sales and distribution network
- Focus on innovation
Weaknesses
- Smaller market share compared to larger competitors
- Dependence on key suppliers
- Exposure to regulatory risks
Opportunities
- Expanding into emerging markets
- Developing new products through research and development
- Acquiring complementary businesses
- Capitalizing on the growing demand for minimally invasive procedures
Threats
- Intense competition from larger players
- Pricing pressure from healthcare providers
- Stringent regulatory requirements
- Product liability claims
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- STRY
Competitive Landscape
CONMED competes with larger medical device companies. It differentiates itself through focused product lines and specialized customer service.
Major Acquisitions
Biorez, Inc.
- Year: 2022
- Acquisition Price (USD millions): 85
- Strategic Rationale: Strengthens CONMED's sports medicine portfolio with innovative bio-inductive solutions.
Growth Trajectory and Initiatives
Historical Growth: CONMED has experienced moderate growth through a combination of organic initiatives and strategic acquisitions.
Future Projections: Future growth projections depend on analyst estimates and market conditions.
Recent Initiatives: Recent initiatives include new product launches and geographic expansion into high-growth markets.
Summary
CONMED is a mid-sized medical technology company with a strong position in the orthopedic and general surgery markets. Its diversified product portfolio and focus on innovation are working well, but it faces intense competition from larger players. CONMED needs to capitalize on growth opportunities in emerging markets and continue to invest in research and development to maintain its competitive edge and watch out for regulatory risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research Reports
- CONMED Investor Relations
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CONMED Corporation
Exchange NYSE | Headquaters Largo, FL, United States | ||
IPO Launch date 1987-07-23 | President, CEO & Director Mr. Patrick J. Beyer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3900 | Website https://www.conmed.com |
Full time employees 3900 | Website https://www.conmed.com | ||
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.